Luca Faconti1,2,3, Charlotte Elizabeth Mills2,3, Virginia Govoni2,3, Haotian Gu1,3, Steven Morant4, Benju Jiang1,3, J Kennedy Cruickshank2,3, Andrew James Webb1,3. 1. Department of Clinical Pharmacology, School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre, London, UK. 2. Department of Nutritional Sciences, School of Life Course Sciences, King's College London, London, UK. 3. Biomedical Research Centre, Clinical Research Facility, Guy's and St Thomas' NHS Foundation Trust, London, UK. 4. Medicines Monitoring Unit (MEMO), University of Dundee, Dundee, UK.
Abstract
AIMS: The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO3 - ), a potential tolerance-free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). METHODS: A subsample of participants in our double-blind, randomized, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent-to-treat. RESULTS:Nitrate-containing juice (n = 40) decreased left ventricular (LV) end-diastolic volume {-6.3 [95% confidence interval (CI) -11.1, -1.6] ml} and end-systolic volume [-3.2 (95% CI -5.9, -0.5) ml], and increased end-diastolic mass/volume ratio [+0.04 (95% CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [-0.01 (95% CI -0.02, -0.00)]. Although spironolactone reduced LV mass index relative to baseline [-1.48 (95% CI -2.08, -0.88) g m-2.7 ], there was no difference vs. doxazosin [-0.85 (95% CI -1.76, 0.05) g m-2.7 ]. Spironolactone also decreased the E/A ratio [-0.12 (95% CI -0.19, -0.04)] and increased S' (a tissue-Doppler systolic function index) by 0.52 (95% CI 0.05, 1.0) cm s-1 . BP did not differ between the juices, or between the drugs. CONCLUSIONS: Six months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic-diastolic function, although confirmatory, were independent of BP.
RCT Entities:
AIMS: The aims of the present study were to explore whether a long-term intervention with dietary nitrate [(NO3 - ), a potential tolerance-free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). METHODS: A subsample of participants in our double-blind, randomized, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent-to-treat. RESULTS:Nitrate-containing juice (n = 40) decreased left ventricular (LV) end-diastolic volume {-6.3 [95% confidence interval (CI) -11.1, -1.6] ml} and end-systolic volume [-3.2 (95% CI -5.9, -0.5) ml], and increased end-diastolic mass/volume ratio [+0.04 (95% CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [-0.01 (95% CI -0.02, -0.00)]. Although spironolactone reduced LV mass index relative to baseline [-1.48 (95% CI -2.08, -0.88) g m-2.7 ], there was no difference vs. doxazosin [-0.85 (95% CI -1.76, 0.05) g m-2.7 ]. Spironolactone also decreased the E/A ratio [-0.12 (95% CI -0.19, -0.04)] and increased S' (a tissue-Doppler systolic function index) by 0.52 (95% CI 0.05, 1.0) cm s-1 . BP did not differ between the juices, or between the drugs. CONCLUSIONS: Six months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic-diastolic function, although confirmatory, were independent of BP.
Authors: Hossam A Shaltout; Joel Eggebeen; Anthony P Marsh; Peter H Brubaker; Paul J Laurienti; Jonathan H Burdette; Swati Basu; Ashley Morgan; Patricia C Dos Santos; James L Norris; Timothy M Morgan; Gary D Miller; W Jack Rejeski; Amret T Hawfield; Debra I Diz; J Thomas Becton; Daniel B Kim-Shapiro; Dalane W Kitzman Journal: Nitric Oxide Date: 2017-05-23 Impact factor: 4.427
Authors: Wojciech Kosmala; Monika Przewlocka-Kosmala; Hanna Szczepanik-Osadnik; Andrzej Mysiak; Thomas H Marwick Journal: Heart Date: 2013-01-23 Impact factor: 5.994
Authors: Abdul R Maher; Alexandra B Milsom; Prasad Gunaruwan; Khalid Abozguia; Ibrar Ahmed; Rebekah A Weaver; Philip Thomas; Houman Ashrafian; Gustav V R Born; Philip E James; Michael P Frenneaux Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Anna K Y Chan; John E Sanderson; Tian Wang; Wynnie Lam; Gabriel Yip; Mei Wang; Yat-Yin Lam; Yan Zhang; Leata Yeung; Eugene B Wu; Wilson W M Chan; John T H Wong; Nina So; Cheuk-Man Yu Journal: J Am Coll Cardiol Date: 2007-07-30 Impact factor: 24.094
Authors: Sami A Omar; Henry Fok; Katharina D Tilgner; Ashok Nair; Joanne Hunt; Benyu Jiang; Paul Taylor; Phil Chowienczyk; Andrew J Webb Journal: Circulation Date: 2014-12-22 Impact factor: 29.690
Authors: Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Luca Faconti; Charlotte Elizabeth Mills; Virginia Govoni; Haotian Gu; Steven Morant; Benju Jiang; J Kennedy Cruickshank; Andrew James Webb Journal: Br J Clin Pharmacol Date: 2018-11-13 Impact factor: 4.335
Authors: Sophie R Sayers; Rebecca L Beavil; Nicholas H F Fine; Guo C Huang; Pratik Choudhary; Kamila J Pacholarz; Perdita E Barran; Sam Butterworth; Charlotte E Mills; J Kennedy Cruickshank; Marta P Silvestre; Sally D Poppitt; Anne-Thea McGill; Gareth G Lavery; David J Hodson; Paul W Caton Journal: Diabetologia Date: 2019-11-15 Impact factor: 10.122